MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer

International Journal of Cancer

Volumn 136, Issue 12, 2015, Pages 2811-2821

  Renaud, Florence ^a,b,c   Vincent, Audrey ^a,b,c   Mariette, Christophe ^a,b,c   Crépin, Michel ^b   Stechly, Laurence ^a,b   Truant, Stéphanie ^a,b,c   Copin, Marie Christine ^a,b,c   Porchet, Nicole ^a,b,c   Leteurtre, Emmanuelle ^a,b,c   Van Seuningen, Isabelle ^a,b,c   Buisine, Marie Pierre ^a,b,c  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

Author keywords

epigenetics; hypomethylation; mucinous cancer; mutator pathway

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MUCIN 2; MUCIN 4; MUCIN 5AC; PROTEIN P53; AZACITIDINE; BRAF PROTEIN, HUMAN; DECITABINE; KRAS PROTEIN, HUMAN; MUC5AC PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; BRAF GENE; CLINICAL FEATURE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DISEASE ACTIVITY; DNA METHYLATION; FEMALE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MSI GENE; MUC5AC GENE; MUCIN 2 GENE; MUCIN 4 GENE; ONCOGENE; ONCOGENE K RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; COLORECTAL TUMOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUCIN 5AC; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84927574385     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29342     Document Type: Article

References (43)

1. Center MM, Jemal A, Ward E,. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688-94.
2. Grady WM, Carethers JM,. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135: 1079-99.
3. Deng G, Chen A, Hong J, et al. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999; 59: 2029-33.
4. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009; 76: 1-18.
5. Jass JR,. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-30.
6. Biemer-Hüttmann AE, Walsh MD, McGuckin MA, et al. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. Clin Cancer Res 2000; 6: 1909-16.
7. Hollingsworth MA, Swanson BL,. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 1: 45-60.
8. Bara J, Nardelli J, Gadenne C, et al. Differences in the expression of mucus-associated antigens between proximal and distal human colon adenocarcinomas. Br J Cancer 1984; 49: 495-501.
9. Blank M, Klussmann E, Krüger-Krasagakes S, et al. Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological types. Int J Cancer 1994; 59: 301-306.
10. Chang SK, Dohrman AF, Basbaum CB, et al. Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer. Gastroenterology 1994; 107: 28-36.
11. Buisine MP, Janin A, Maunoury V, et al. Aberrant expression of a human mucin gene (MUC5AC) in rectosigmoid villous adenoma. Gastroenterology 1996; 110: 84-91.
12. Kim DH, Kim JW, Cho JH, et al. Expression of mucin core proteins, trefoil factors, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum. Int J Oncol 2005; 27: 957-64.
13. Shanmugam C, Jhala NC, Katkoori VR, et al. Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer 2010; 116: 3577-86.
14. Vincent A, Perrais M, Desseyn JL, et al. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene 2007; 26: 6566-76.
15. Vincent A, Ducourouble MP, Van Seuningen I,. Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases. FASEB J 2008; 22: 3035-45.
16. Hanski C, Riede E, Gratchev A, et al. MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation. Lab Invest 1997; 77: 685-95.
17. Gratchev A, Siedow A, Bumke-Vogt C, et al. Regulation of the intestinal mucin MUC2 gene expression in vivo: evidence for the role of promoter methylation. Cancer Lett 2001; 168: 71-80.
18. Okudaira K, Kakar S, Cun L, et al. MUC2 gene promoter methylation in mucinous and non-mucinous colorectal cancer tissues. Int J Oncol 2010; 36: 765-75.
19. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002; 123: 1804-11.
20. Edge SB, Byrd DR, Carducci MA, et al. AJCC hindgut taskforce: colon and rectum. In: AJCC Cancer Staging Manual, 7th edn. New York: Springer, 2009. 143-46.
21. Bosman F, Carneiro F, Hruban R, et al. World Health Organization classification of tumors of the digestive system. Lyon: IARC Press, 2010.
22. Buisine MP, Desreumaux P, Leteurtre E, et al. Mucin gene expression in intestinal epithelial cells in Crohn's disease. Gut 2001; 49: 544-51.
23. Cappia S, Righi L, Mirabelli D, et al. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 2008; 130: 58-64.
24. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-93.
25. Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007; 9: 305-14.
26. Hesson LB, Wilson R, Morton D, et al. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 2005; 24: 3987-94.
27. Canzian F, Salovaara R, Hemminki A, et al. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996; 56: 3331-37.
28. You JF, Hsieh LL, Changchien CR, et al. Inverse effects of mucin on survival of matched hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer patients. Clin Cancer Res 2006; 12: 4244-50.
29. Walsh MD, Clendenning M, Williamson E, et al. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol 2013; 26: 1642-56.
30. Irahara N, Nosho K, Baba Y, et al. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn 2010; 12: 177-83.
31. Mesquita P, Peixoto AJ, Seruca R, et al. Role of site-specific promoter hypomethylation in aberrant MUC2 mucin expression in mucinous gastric carcinomas. Cancer Lett 2003; 189: 129-36.
32. Hamada T, Goto M, Tsutsumida H, et al. Mapping of the methylation pattern of the MUC2 promoter in pancreatic cancer cell lines, using bisulfite genomic sequencing. Cancer Lett 2005; 227: 175-84.
33. Yamada N, Nishida Y, Tsutsumida H, et al. Promoter CpG methylation in cancer cells contributes to the regulation of MUC4. Br J Cancer 2009; 100: 344-51.
34. Ho JJ, Han SW, Pan PL, et al. Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells. Int J Oncol 2003; 22: 273-79.
35. Yamada N, Nishida Y, Yokoyama S, et al. Expression of MUC5AC, an early marker of pancreatobiliary cancer, is regulated by DNA methylation in the distal promoter region in cancer cells. J Hepatobiliary Pancreat Sci 2010; 17: 844-54.
36. Perrais M, Pigny P, Copin MC, et al. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 2002; 277: 32258-67.
37. Leow CC, Romero MS, Ross S, et al. HATH1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells. Cancer Res 2004; 64: 6050-57.
38. Park ET, Oh HK, Gum JR, Jr, et al. HATH1 expression in mucinous cancers of the colorectum and related lesions. Clin Cancer Res 2006; 12: 5403-10.
39. Blache P, van de Wetering M, Duluc I, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 2004; 166: 37-47.
40. Park ET, Gum JR, Kakar S, et al. Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions. Int J Cancer 2008; 122: 1253-60.
41. Nagae G, Isagawa T, Shiraki N, et al. Tissue-specific demethylation in CpG-poor promoters during cellular differentiation. Hum Mol Genet 2011; 20: 2710-21.
42. Popat S, Hubner R, Houlston RS,. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-18.
43. Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012; 104: 1635-46.